Moderna Tokenized Stock (Reality) Live Price Update & Market Capitalization

Moderna Tokenized Stock (Reality) RMRNA #2932

$198.68 19.1% (1d)

Market Overview

Moderna Tokenized Stock (Reality) current market price is $198.68 with a 24 hour trading volume of $572.36K. The total available supply of Moderna Tokenized Stock (Reality) is 5,065 RMRNA. It has secured Rank 2932 in the cryptocurrency market with a marketcap of $1,006.40K. The RMRNA price is 0.14% up in the last one hour.


The high price of the Moderna Tokenized Stock (Reality) is $249.49 and low price is $180.92 in the last 24 hours. Live prices from all markets and coin market Capitalization. Stay up to date with the latest price movements. Check our coin stats data and see when there is an opportunity to buy or sell at best price in the market.

Moderna Tokenized Stock (Reality) Rank

2932

Moderna Tokenized Stock (Reality) Price

$198.68

Market Cap

$1,006.40K 37.56%

Fully Diluted Valuation

$1,006.40K

Trading Volume(24h)

$572.36K

Circulating Supply

5,065 RMRNA

Total Supply

5,065 RMRNA

Max Supply

(Not Available)

High(24h)

$249.49

Low(24h)

$180.92

All-time High

$254.14 21.82%
21 Oct 2026

All-time Low

$141.11 40.8%
15 Sep 2026

Cryptocurrency Moderna Tokenized Stock (Reality) Calculator

Want to convert more cryptocurrencies?

Moderna Tokenized Stock (Reality) Price Chart

1h

0.14%

24h

19.1%

7d

15.67%

14d

1.46%

30d

8.89%

60d

0%

200d

0%

1y

0%

No historical data available for .

Moderna Tokenized Stock (Reality) Market Cap Chart

Moderna Tokenized Stock (Reality) Markets

Compare live prices of Moderna Tokenized Stock (Reality) on top exchanges.

#ExchangePairPriceVolume(24h)Trust Score
BitgetRMRNA/USDT $198.35$572,351

About Moderna Tokenized Stock (Reality)

Moderna engages in the research, development, and manufacturing of prescription drugs for infectious diseases and other conditions. Its products and candidate pipelines are entirely based on its messenger RNA (mRNA) technology platform. The business covers preclinical molecular design, advancement of human clinical trials, and scaled production of vaccines. The company primarily supplies approved biological products and related vaccines to national governments and healthcare institutions.